Extramedullary Relapse (extramedullary + relapse)

Distribution by Scientific Domains


Selected Abstracts


Pseudohypopyon: Extramedullary relapse of acute myelogenous leukemia with poor prognosis

PEDIATRIC BLOOD & CANCER, Issue 7 2009
William C. Petersen MD
Abstract An 11-month-old female presented to the emergency department with a 2-week history of fever, increasing fussiness, emesis, and decreased urine output. She was diagnosed with acute myelogenous leukemia. Systemic chemotherapy with intensified intrathecal cytarabine was started, and the patient achieved a clinical remission after the first course of induction. Towards the end of her second course of induction she developed pseudohypopyon in each eye on consecutive days, heralding a central nervous system relapse. Pediatr Blood Cancer 2009;52:885,887. © 2008 Wiley-Liss, Inc. [source]


Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse,

PEDIATRIC BLOOD & CANCER, Issue 5 2004
Blythe Thomson MD
Abstract Background Approximately 25% of children newly diagnosed with acute lymphoblastic leukemia (ALL) will eventually experience leukemic relapse, with bone marrow being the most common site of recurrence. The ability to achieve a durable second remission is complicated by toxicity and resistant disease. We report a novel combination of chemotherapy for relapsed pediatric ALL. Procedure Thirty pediatric patients with relapsed medullary (n,=,18) and extra-medullary (n,=,12) ALL were enrolled at three pediatric institutions. Following receipt of induction and the first Block A and Block B of intensification, each patient was evaluated for toxicity, efficacy in achieving remission, and long-term survival. Additionally, minimal residual disease (MRD) detection by multidimensional flow cytometry (MDF) was performed. Results During induction, the major non-hematopoeitic toxicities were mucositis (30% of patients) and bacteremia (50% of patients). Two patients (7%) died of toxicity during induction. Toxicity during intensification Block 1A and 1B was markedly reduced. Eight-nine percent of patients with marrow disease achieved a remission following induction and intensification. The event-free survival (EFS) for all patients at 2 and 4 years were 60% (95% CI: 42,78%) and 49% (95% CI: 30,68%), respectively. Conclusions This regimen for patients with relapsed ALL was successful in achieving a second remission for the majority of patients with acceptable toxicity. © 2004 Wiley-Liss, Inc. [source]


Thalidomide is effective for extramedullary relapse of multiple myeloma post-allogeneic bone marrow transplantation

BRITISH JOURNAL OF HAEMATOLOGY, Issue 2 2001
James J. Biagi
[source]


Late relapse of a light-chain myeloma as extramedullary plasmacytoma of the thyroid gland after second allogeneic stem-cell transplantation

CLINICAL TRANSPLANTATION, Issue 6 2009
Evren Özdemir
Abstract:, We present a rare experience with a myeloma patient who had a late relapse as isolated extramedullary plasmacytoma of the thyroid gland after a second allogeneic transplantation. We give PET/CT scan findings at diagnosis and during follow up of the disease after subsequent management. The possible pathogenesis of the late extramedullary relapse of myeloma after allogeneic stem-cell transplantation and management options are discussed. [source]